Viatris Inc. – NASDAQ:VTRS
Viatris stock price today
$10.71
-1.76
-14.18%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 3 hours
Viatris stock price monthly change
+11.03%
month
Viatris stock price quarterly change
+11.03%
quarter
Viatris stock price yearly change
+15.88%
year
Viatris key metrics
Market Cap | 14.92B |
Enterprise value | 30.63B |
P/E | -16.86 |
EV/Sales | 2.03 |
EV/EBITDA | 12.18 |
Price/Sales | 0.99 |
Price/Book | 0.75 |
PEG ratio | 0.07 |
EPS | -0.04 |
Revenue | 15.34B |
EBITDA | 3.26B |
Income | -56.1M |
Revenue Q/Q | -1.93% |
Revenue Y/Y | -2.90% |
Profit margin | -5.87% |
Oper. margin | -1.76% |
Gross margin | 40.26% |
EBIT margin | -1.76% |
EBITDA margin | 21.29% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeViatris stock price history
Viatris stock forecast
Viatris financial statements
| Jun 2023 | 3.91B | 264M | 6.74% |
|---|---|---|---|
| Sep 2023 | 3.94B | 331.6M | 8.41% |
| Dec 2023 | 3.82B | -765.6M | -20.02% |
| Mar 2024 | 3.65B | 113.9M | 3.11% |
| Mar 2024 | 3.65B | 113.9M | 3.11% |
|---|---|---|---|
| Sep 2025 | 3.90B | 831.06M | 21.3% |
| Oct 2025 | 3.90B | 822.46M | 21.08% |
| Dec 2025 | 3.91B | 798.27M | 20.39% |
Analysts Price target
Financials & Ratios estimates
Paying a dividend while loss making.
3.84%
Yield TTM
| Payout ratio | -65.15% |
|---|
| 2019 | |
|---|---|
| 2020 | |
| 2021 | 2.44% |
| 2022 | 4.31% |
| 2023 | 4.43% |
| Jun 2023 | 48695200000 | 27.85B | 57.2% |
|---|---|---|---|
| Sep 2023 | 48742600000 | 27.87B | 57.19% |
| Dec 2023 | 47685500000 | 27.21B | 57.08% |
| Mar 2024 | 47343700000 | 27.32B | 57.73% |
| Jun 2023 | 514.9M | -76.6M | -303.5M |
|---|---|---|---|
| Sep 2023 | 834.1M | -53.8M | -97.6M |
| Dec 2023 | 479.4M | 115.8M | -926.1M |
| Mar 2024 | 614.6M | -154.3M | -425.6M |
Viatris alternative data
Areas of Focus
| 21 May 2023 | 7 | 73 | 2 | 2 | 6 |
|---|---|---|---|---|---|
| 28 May 2023 | 7 | 74 | 2 | 2 | 6 |
| 4 Jun 2023 | 7 | 74 | 2 | 2 | 7 |
| 11 Jun 2023 | 7 | 72 | 2 | 2 | 8 |
| 18 Jun 2023 | 7 | 79 | 2 | 2 | 9 |
| 25 Jun 2023 | 7 | 76 | 2 | 3 | 9 |
| 2 Jul 2023 | 8 | 75 | 2 | 3 | 11 |
| 9 Jul 2023 | 8 | 74 | 2 | 2 | 11 |
| 16 Jul 2023 | 8 | 77 | 2 | 3 | 11 |
| 23 Jul 2023 | 7 | 77 | 2 | 3 | 11 |
| 30 Jul 2023 | 7 | 76 | 2 | 2 | 10 |
| 6 Aug 2023 | 6 | 77 | 2 | 3 | 10 |
| 13 Aug 2023 | 7 | 75 | 2 | 2 | 10 |
| 20 Aug 2023 | 6 | 74 | 2 | 2 | 9 |
| 27 Aug 2023 | 6 | 93 | 2 | 2 | 9 |
| 3 Sep 2023 | 7 | 82 | 2 | 2 | 9 |
| 10 Sep 2023 | 5 | 72 | 2 | 2 | 8 |
| 17 Sep 2023 | 7 | 75 | 2 | 2 | 9 |
| 24 Sep 2023 | 7 | 74 | 2 | 2 | 9 |
| 1 Oct 2023 | 6 | 69 | 2 | 2 | 7 |
Key Viatris Brands
| 19 Feb 2023 | 80 | 44 | 2 | 4 | 3 |
|---|---|---|---|---|---|
| 26 Feb 2023 | 76 | 43 | 2 | 5 | 2 |
| 5 Mar 2023 | 77 | 46 | 2 | 5 | 2 |
| 12 Mar 2023 | 77 | 46 | 3 | 5 | 3 |
| 19 Mar 2023 | 80 | 45 | 2 | 5 | 3 |
| 26 Mar 2023 | 76 | 45 | 2 | 5 | 3 |
| 2 Apr 2023 | 80 | 43 | 3 | 5 | 2 |
| 9 Apr 2023 | 79 | 49 | 2 | 6 | 3 |
| 16 Apr 2023 | 82 | 46 | 2 | 4 | 4 |
| 23 Apr 2023 | 85 | 45 | 3 | 4 | 2 |
| 30 Apr 2023 | 81 | 52 | 4 | 5 | 4 |
| 7 May 2023 | 82 | 47 | 3 | 4 | 2 |
| 14 May 2023 | 84 | 46 | 2 | 6 | 3 |
| 21 May 2023 | 74 | 42 | 2 | 4 | 2 |
| 28 May 2023 | 84 | 47 | 2 | 6 | 2 |
| 4 Jun 2023 | 80 | 50 | 3 | 5 | 3 |
| 11 Jun 2023 | 68 | 44 | 1 | 5 | 2 |
| 18 Jun 2023 | 77 | 48 | 2 | 5 | 1 |
| 25 Jun 2023 | 81 | 51 | 3 | 5 | 3 |
| 2 Jul 2023 | 74 | 48 | 2 | 4 | 3 |
Key Viatris Brands 2
| 19 Feb 2023 | 2 | 8 | 49 | 3 | 1 |
|---|---|---|---|---|---|
| 26 Feb 2023 | 2 | 8 | 53 | 3 | 1 |
| 5 Mar 2023 | 2 | 9 | 54 | 4 | 1 |
| 12 Mar 2023 | 1 | 9 | 51 | 3 | 1 |
| 19 Mar 2023 | 2 | 8 | 60 | 4 | 1 |
| 26 Mar 2023 | 2 | 9 | 52 | 3 | 1 |
| 2 Apr 2023 | 1 | 8 | 47 | 4 | 1 |
| 9 Apr 2023 | 2 | 8 | 46 | 4 | 1 |
| 16 Apr 2023 | 2 | 8 | 49 | 4 | 1 |
| 23 Apr 2023 | 2 | 8 | 47 | 4 | 1 |
| 30 Apr 2023 | 2 | 9 | 44 | 4 | 1 |
| 7 May 2023 | 2 | 9 | 48 | 4 | 1 |
| 14 May 2023 | 2 | 8 | 48 | 4 | 1 |
| 21 May 2023 | 2 | 7 | 41 | 4 | 1 |
| 28 May 2023 | 2 | 8 | 45 | 4 | 1 |
| 4 Jun 2023 | 2 | 9 | 43 | 4 | 1 |
| 11 Jun 2023 | 2 | 8 | 45 | 3 | 1 |
| 18 Jun 2023 | 2 | 8 | 42 | 4 | 1 |
| 25 Jun 2023 | 2 | 8 | 41 | 4 | 1 |
| 2 Jul 2023 | 2 | 9 | 45 | 3 | 1 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Aug 2023 | 437 |
|---|---|
| Sep 2023 | 450 |
| Oct 2023 | 471 |
| Nov 2023 | 471 |
| Dec 2023 | 417 |
| Jan 2024 | 420 |
| Feb 2024 | 357 |
| Apr 2024 | 368 |
| May 2024 | 395 |
| Jun 2024 | 381 |
| Jan 2025 | 327 |
| Feb 2025 | 311 |
| May 2025 | 280 |
| Aug 2023 | 38,000 |
|---|---|
| Sep 2023 | 38,000 |
| Oct 2023 | 38,000 |
| Nov 2023 | 38,000 |
| Dec 2023 | 38,000 |
| Jan 2024 | 38,000 |
| Feb 2024 | 38,000 |
| Mar 2024 | 38,000 |
| Apr 2024 | 38,000 |
| May 2024 | 38,000 |
| Jun 2024 | 33,000 |
| Jul 2024 | 33,000 |
Viatris other data
73.07%
+0.38%
of VTRS is owned by hedge funds
935
-16
886.40M
+7.75M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2023 | 0 | 14937 |
| Dec 2023 | 0 | 4000 |
| Jan 2024 | 0 | 4000 |
| Mar 2024 | 0 | 274353 |
| May 2024 | 0 | 89419 |
| Jun 2024 | 0 | 349960 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | MALIK RAJIV director | Common Stock | 264,300 | $10.18 | $2,690,310 | ||
Sale | MALIK RAJIV director | Common Stock | 85,660 | $10.52 | $900,715 | ||
Sale | ROMAN BRIAN officer: Chief Legal Officer | Common Stock | 89,419 | $10.38 | $928,437 | ||
Sale | MAURO ANTHONY officer: See Rema.. | Common Stock | 250,000 | $12.1 | $3,023,750 | ||
Sale | CAMPBELL PAUL officer: See Remarks | Common Stock | 24,353 | $12.33 | $300,272 | ||
Option | CAMPBELL PAUL officer: See Remarks | Common Stock | 17,872 | N/A | N/A | ||
Option | CAMPBELL PAUL officer: See Remarks | Common Stock | 1,555 | N/A | N/A | ||
Option | CAMPBELL PAUL officer: See Remarks | Restricted Stock Units | 17,872 | N/A | N/A | ||
Option | CAMPBELL PAUL officer: See Remarks | Dividend Equivalent Units | 1,554 | N/A | N/A | ||
Option | MAURO ANTHONY officer: See Rema.. | Common Stock | 36,601 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 7 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Robert J. Coury (1961) Executive Chairman | $16,610,000 |
| Mr. Rajiv Malik (1961) Pres & Executive Director | $6,870,000 |
| Mr. Anthony Mauro (1973) Pres of Developed Markets | $3,540,000 |
| Mr. Michael Goettler (1967) Chief Executive Officer & Executive Director | $3,070,000 |
| Mr. Sanjeev Narula (1961) Chief Financial Officer | $2,500,000 |
Viatris: The Problem With The Business Model
Why Investors Should Watch Teva Despite Regional Risks
Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
Viatris: Consolidate In 2025, Win In 2026 - How 'Phase 2' Of Business Plan May Play Out
Top 4 Immunology Stocks Poised For Growth In 2025
Teva Pharmaceutical: Buy This Bargain Before It's Gone
Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.
Viatris Stock Is Still Worth Buying
From Euphoria To Reality: Viatris' Tale Of Market Whirlwind
-
What's the price of Viatris stock today?
One share of Viatris stock can currently be purchased for approximately $10.71.
-
When is Viatris's next earnings date?
Unfortunately, Viatris's (VTRS) next earnings date is currently unknown.
-
Does Viatris pay dividends?
Yes, Viatris pays dividends and its trailing 12-month yield is 3.85% with -65% payout ratio.It means that the company is paying a dividend while loss making. The last Viatris stock dividend of $0.11 was paid on 16 Dec 2021.
-
How much money does Viatris make?
Viatris has a market capitalization of 14.92B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 5.14% to 15.43B US dollars.
-
What is Viatris's stock symbol?
Viatris Inc. is traded on the NASDAQ under the ticker symbol "VTRS".
-
What is Viatris's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Viatris?
Shares of Viatris can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Viatris's key executives?
Viatris's management team includes the following people:
- Mr. Robert J. Coury Executive Chairman(age: 64, pay: $16,610,000)
- Mr. Rajiv Malik Pres & Executive Director(age: 64, pay: $6,870,000)
- Mr. Anthony Mauro Pres of Developed Markets(age: 52, pay: $3,540,000)
- Mr. Michael Goettler Chief Executive Officer & Executive Director(age: 58, pay: $3,070,000)
- Mr. Sanjeev Narula Chief Financial Officer(age: 64, pay: $2,500,000)
-
How many employees does Viatris have?
As Jul 2024, Viatris employs 33,000 workers, which is 13% less then previous quarter.
-
When Viatris went public?
Viatris Inc. is publicly traded company for more then 45 years since IPO on 17 Mar 1980.
-
What is Viatris's official website?
The official website for Viatris is viatris.com.
-
Where are Viatris's headquarters?
Viatris is headquartered at 1000 Mylan Boulevard, Canonsburg, PA.
-
How can i contact Viatris?
Viatris's mailing address is 1000 Mylan Boulevard, Canonsburg, PA and company can be reached via phone at +7 245141800.
Viatris company profile:
Viatris Inc.
viatris.comExchange:
NASDAQ
Full time employees:
32,000
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
1000 Mylan Boulevard
Canonsburg, PA 15317
Canonsburg, PA 15317
CIK: 0001792044
ISIN: US92556V1061
CUSIP: 92556V106
